Retraction: Arnebin-1 promotes angiogenesis by inducing eNOS, VEGF and HIF-1α expression through the PI3K-dependent pathway (International Journal of Molecular Medicine (2015) 36 (685-697) DOI: 10.3892/ijmm.2015.2292);Arnebin-1 promotes angiogenesis by inducing eNOS, VEGF and HIF-1α expression through the PI3K-dependent pathway

International Journal of Molecular Medicine

Volumn 36, Issue 3, 2015, Pages 685-697

  Zeng, Zhi ^a   Huang, Wen Dong ^a   Gao, Qi ^a   Su, Mei Ling ^a   Yang, Yong Fei ^a   Liu, Zhao Chun ^a   Zhu, Bang Hao ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Angiogenesis; Arnebin 1; Diabetic wound; Endothelial nitric oxide synthase; Hypoxia inducible factor; Phosphatidylinositol 3 kinase dependent pathway; Vascular endothelial growth factor

Indexed keywords

1,4 NAPHTHOQUINONE DERIVATIVE; ARNEBIN 1; CD31 ANTIGEN; CYCLINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FOCAL ADHESION KINASE; GLUCOSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; WOUND HEALING PROMOTING AGENT; ANGIOGENIC FACTOR; BETA, BETA-DIMETHYLACRYLSHIKONIN; NAPHTHOQUINONE; VASCULOTROPIN A;

ALLOXAN-INDUCED DIABETES MELLITUS; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BODY WEIGHT; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; MALE; MTT ASSAY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; WESTERN BLOTTING; WOUND HEALING; ANIMAL; CYTOLOGY; DIABETES COMPLICATIONS; DRUG EFFECTS; METABOLISM; SPRAGUE DAWLEY RAT;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; DIABETES COMPLICATIONS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; NAPHTHOQUINONES; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHATIDYLINOSITOL 3-KINASES; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 84938079277     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/IJMM.2023.5241     Document Type: Erratum

References (46)

1. Boulton AJ: The diabetic foot: Grand overview, epidemiology and pathogenesis. Diabetes Metab Res Rev 24 (Suppl 1): S3-S6, 2008.
2. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G and Apelqvist J: The global burden of diabetic foot disease. Lancet 366: 1719-1724, 2005.
3. Bartus CL and Margolis DJ: Reducing the incidence of foot ulceration and amputation in diabetes. Curr Diab Rep 4: 413-418, 2004.
4. Macfarlane RM and Jeffcoate WJ: Factors contributing to the presentation of diabetic foot ulcers. Diabet Med 14: 867-870, 1997.
5. Ruffieux P, Hommel L and Saurat JH: Long-term assessment of chronic leg ulcer treatment by autologous skin grafts. Dermatology 195: 77-80, 1997.
6. Tandara AA and Mustoe TA: Oxygen in wound healing - more than a nutrient. World J Surg 28: 294-300, 2004.
7. Covello KL and Simon MC: HIFs, hypoxia, and vascular development. Curr Top Dev Biol 62: 37-54, 2004.
8. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP and Gurtner GC: Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10: 858-864, 2004.
9. Kelly BD, Hackett SF, Hirota K, Oshima Y, Cai Z, Berg-Dixon S, Rowan A, Yan Z, Campochiaro PA and Semenza GL: Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 93: 1074-1081, 2003.
10. Li W, Li Y, Guan S, Fan J, Cheng CF, Bright AM, Chinn C, Chen M and Woodley DT: Extracellular heat shock protein-90alpha: Linking hypoxia to skin cell motility and wound healing. EMBO J 26: 1221-1233, 2007.
11. Thangarajah H, Yao D, Chang EI, Shi Y, Jazayeri L, Vial IN, Galiano RD, Du XL, Grogan R, Galvez MG, et al: The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci USA 106: 13505-13510, 2009.
12. Carmeliet P: VEGF as a key mediator of angiogenesis in cancer. Oncology 69 (Suppl 3): 4-10, 2005.
13. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
14. Neufeld G, Cohen T, Gengrinovitch S and Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13: 9-22, 1999.
15. Frank S, Hübner G, Breier G, Longaker MT, Greenhalgh DG and Werner S: Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem 270: 12607-12613, 1995.
16. Holmes K, Roberts OL, Thomas AM and Cross MJ: Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 19: 2003-2012, 2007.
17. Olsson AK, Dimberg A, Kreuger J and Claesson-Welsh L: VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371, 2006.
18. Meadows KN, Bryant P and Pumiglia K: Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. J Biol Chem 276: 49289-49298, 2001.
19. Takahashi T, Ueno H and Shibuya M: VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18: 2221-2230, 1999.
20. Ko SH, Nauta A, Morrison SD, Zhou H, Zimmermann A, Gurtner GC, Ding S and Longaker MT: Antimycotic ciclopirox olamine in the diabetic environment promotes angiogenesis and enhances wound healing. PLoS One 6: e27844, 2011.
21. Papageorgiou VP, Assimopoulou AN and Ballis AC: Alkannins and shikonins: a new class of wound healing agents. Curr Med Chem 15: 3248-3267, 2008.
22. Sidhu GS, Singh AK, Banaudha KK, Gaddipati JP, Patnaik GK and Maheshwari RK: Arnebin-1 accelerates normal and hydrocortisone-induced impaired wound healing. J Invest Dermatol 113: 773-781, 1999.
23. Zeng Z and Zhu BH: Arnebin-1 promotes the angiogenesis of human umbilical vein endothelial cells and accelerates the wound healing process in diabetic rats. J Ethnopharmacol 154: 653-662, 2014.
24. Oyibo SO, Jude EB, Tarawneh I, Nguyen HC, Armstrong DG, Harkless LB and Boulton AJ: The effects of ulcer size and site, patient?s age, sex and type and duration of diabetes on the outcome of diabetic foot ulcers. Diabet Med 18: 133-138, 2001.
25. Armstrong DG, Lavery LA and Harkless LB: Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care 21: 855-859, 1998.
26. Jeffcoate WJ, Chipchase SY, Ince P and Game FL: Assessing the outcome of the management of diabetic foot ulcers using ulcer-related and person-related measures. Diabetes Care 29: 1784-1787, 2006.
27. Martin A, Komada MR and Sane DC: Abnormal angiogenesis in diabetes mellitus. Med Res Rev 23: 117-145, 2003.
28. Falanga V: Wound healing and its impairment in the diabetic foot. Lancet 366: 1736-1743, 2005.
29. Hinchliffe RJ, Valk GD, Apelqvist J, Armstrong DG, Bakker K, Game FL, Hartemann-Heurtier A, Löndahl M, Price PE, van Houtum WH and Jeffcoate WJ: A systematic review of the effectiveness of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metab Res Rev 24 (Suppl 1): S119-S144, 2008.
30. Bao P, Kodra A, Tomic-Canic M, Golinko MS, Ehrlich HP and Brem H: The role of vascular endothelial growth factor in wound healing. J Surg Res 153: 347-358, 2009.
31. Xie L, Zhang M, Dong B, Guan M, Lu M, Huang Z, Gao H and Li X: Improved refractory wound healing with administration of acidic fibroblast growth factor in diabetic rats. Diabetes Res Clin Pract 93: 396-403, 2011.
32. Botusan IR, Sunkari VG, Savu O, Catrina AI, Grünler J, Lindberg S, Pereira T, Ylä-Herttuala S, Poellinger L, Brismar K, et al: Stabilization of HIF-1α is critical to improve wound healing in diabetic mice. Proc Natl Acad Sci USA 105: 19426-19431, 2008.
33. Stroka DM, Burkhardt T, Desbaillets I, Wenger RH, Neil DA, Bauer C, Gassmann M and Candinas D: HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J 15: 2445-2453, 2001.
34. Galiano RD, Tepper OM, Pelo CR, Bhatt KA, Callaghan M, Bastidas N, Bunting S, Steinmetz HG and Gurtner GC: Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol 164: 1935-1947, 2004.
35. Carmeliet P: Mechanisms of angiogenesis and arteriogenesis. Nat Med 6: 389-395, 2000.
36. Vranckx JJ, Yao F, Petrie N, Augustinova H, Hoeller D, Visovatti S, Slama J and Eriksson E: In vivo gene delivery of Ad-VEGF121 to full-thickness wounds in aged pigs results in high levels of VEGF expression but not in accelerated healing. Wound Repair Regen 13: 51-60, 2005.
37. Rey S and Semenza GL: Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. Cardiovasc Res 86: 236-242, 2010.
38. Bitto A, Irrera N, Minutoli L, Cal? M, Lo Cascio P, Caccia P, Pizzino G, Pallio G, Micali A, Vaccaro M, et al: Relaxin improves multiple markers of wound healing and ameliorates the disturbed healing pattern of genetically diabetic mice. Clin Sci (Lond) 125: 575-585, 2013.
39. Liu J and Agarwal S: Mechanical signals activate vascular endothelial growth factor receptor-2 to upregulate endothelial cell proliferation during inflammation. J Immunol 185: 1215-1221, 2010.
40. Takahashi T, Yamaguchi S, Chida K and Shibuya M: A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J 20: 2768-2778, 2001.
41. Eliceiri BP, Puente XS, Hood JD, Stupack DG, Schlaepfer DD, Huang XZ, Sheppard D and Cheresh DA: Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. J Cell Biol 157: 149-160, 2002.
42. Holmqvist K, Cross MJ, Rolny C, Hägerkvist R, Rahimi N, Matsumoto T, Claesson-Welsh L and Welsh M: The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J Biol Chem 279: 22267-22275, 2004.
43. Abedi H and Zachary I: Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J Biol Chem 272: 15442-15451, 1997.
44. Avraham HK, Lee TH, Koh Y, Kim TA, Jiang S, Sussman M, Samarel AM and Avraham S: Vascular endothelial growth factor regulates focal adhesion assembly in human brain microvascular endothelial cells through activation of the focal adhesion kinase and related adhesion focal tyrosine kinase. J Biol Chem 278: 36661-36668, 2003.
45. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, Zeiher AM and Dimmeler S: Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 9: 1370-1376, 2003.
46. Everaert BR, Van Craenenbroeck EM, Hoymans VY, Haine SE, Van Nassauw L, Conraads VM, Timmermans JP and Vrints CJ: Current perspective of pathophysiological and interventional effects on endothelial progenitor cell biology: focus on PI3K/AKT/eNOS pathway. Int J Cardiol 144: 350-366, 2010.